Skip to Content
Get key facts and figures about chronic dry eye

Drug interactions between Lumigan and Travatan

Results for the following 2 drugs:
Lumigan (bimatoprost ophthalmic)
Travatan (travoprost ophthalmic)

Interactions between your drugs


travoprost ↔ bimatoprost

Applies to:Travatan (travoprost ophthalmic) and Lumigan (bimatoprost ophthalmic)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Concurrent use of multiple prostaglandin analogs, as well as more frequent administration of a prostaglandin analog than recommended, may reduce the intraocular pressure (IOP) lowering effects of these agents. A case series of 3 patients described IOP elevations of 6 to 23 mmHg two to five weeks after bimatoprost was added to a latanoprost regimen. The precise mechanism of interaction has not been established, although the combination exceeded the dose-response curve, which may have led to the paradoxical effects on IOP. Other factors such as disease state and patient compliance may also have contributed. In a randomized clinical trial of 18 patients with non-advanced primary open angle glaucoma, mean IOP increased by 1.8 mmHg four weeks after the addition of bimatoprost to preexisting latanoprost treatment, but returned to baseline after discontinuation of bimatoprost.

MANAGEMENT: Concomitant administration of two or more prostaglandin analogs, or more frequent administration of a prostaglandin analog than approved by the manufacturers, is generally not recommended.


  1. Doi LM, Melo LA, Prata JA "Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomized clinical trial." Br J Ophthalmol 89 (2005): 547-9
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Herndon LW, Asrani SG, Williams GH, Challa P, Lee PP "Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost." Arch Ophthalmol 120 (2002): 847-9
  5. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
View all 5 references

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.


Prostaglandin agonist ophthalmics

Therapeutic duplication

The recommended maximum number of medicines in the 'prostaglandin agonist ophthalmics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'prostaglandin agonist ophthalmics' category:

  • bimatoprost (active ingredient in Lumigan (bimatoprost ophthalmic))
  • travoprost (active ingredient in Travatan (travoprost ophthalmic))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.